MK4827 Niraparib Cas 1038915-60-4 PARP Inhibitors
MK4827 Niraparib PARP Inhibitors Cas 1038915-60-4
| Product name:MK4827 Niraparib | Purity:99% min |
| CAS NO:1038915-60-4 | Solubility:DMSO : ≥ 32 mg/mL (99.88 mM) |
| Molecular Formula:C19H20N4O | Package:Package according to customer requirements |
| Molecular Weight:320.388 | Storage:Store at -20℃ |
Niraparib, also known as MK4827, is an orally active, potent and selective poly(ADP-Ribose) polymerase (PARP) inhibitor that radiosensitizes human lung and breast cancer cells. Niraparib inhibits PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM respectively. Niraparib is currently in Phase 3 clinical trials for ovarian cancer and BRCA+ breast cancer.
Properties:
Density: 1.34±0.1 g/cm3 (calc.)
Boiling Point: 463.6±45.0 °C (760 mmHg, calc.)
Flash Point: 234.188ºC
PARP Inhibitors Related Products:
Veliparib hcl; Olaparib; XAV-939; Rucaparib; Talazoparib; A-966492; PJ34 HCl; Pamiparib; WIKI4; G007-LK; AZD2461; Saroglitazar; Veliparib
[1]. Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
[2]. Bridges KA, et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5(13):5076-86.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.